399
Participants
Start Date
August 31, 2011
Primary Completion Date
December 31, 2015
Study Completion Date
December 31, 2015
Maraviroc
Maraviroc is a marketed drug for the treatment of HIV-infection. Maraviroc will be supplied in two different oral dose forms, 150mg and 300mg given twice a day. The drug will be dosed according to the recommendations in the product label i.e. with PI/r the dose is 150mg bid except, Maraviroc 300mg bid can be used at the discretion of the investigator if the PI/r is fosamprenavir/r; those randomised to the 2N(t)RTI arm, will receive Maraviroc 300mg bid. Patients randomised to receive Maraviroc will be provided with bottles of Maraviroc which contain a 30-day supply.
Mater Misericordiae University Hospital, Dublin
FUNCEI, Buenos Aires
Hospital Nacional Prof Alejandro Posadas, El Palomar
Hospital Dr Diego Paroissien, Isidro Casanova
Holdsworth House Medical Practice, Sydney
St. Vincent's Hospital, Sydney
Royal Prince Alfred Hospital, Sydney
Westmead Hospital, Sydney
Alfred Hospital, Melbourne
Monash Medical Centre, Melbourne
Brisbane Sexual Health and HIV Service (formerly AMU), Brisbane
Gladstone Road Medical Centre, Bisbane
Nambour General Hospital, Nambour
O'Brien Street Practice, Adelaide
Chulalongkorn University Hospital, Bangkok
Gemeinschaftspraxis Jessen Jessen Stein, Berlin
Dienstleistung centre ID (Baumgarten, MIB medical center for infectious diseases), Berlin
Hospital La Paz,, Madrid
Hospital Principe de Asturias, Madrid
Hospital Regional Carlos Haya de Málaga, Málaga
Klinik für Immunologie und Rheumatologie, Medzinische Hochschule Hannover, Hanover
Hospital General de Leon, León
Universitätsklinikum Düsseldorf, Klinik für Gastroenterologie, Hepatologie und Infektiologie-MX- Amb, Düsseldorf
Virgen Del Rocio University Hospital, Seville
Hospital Civil de Guadalajara, Guadalajara
Service Maladies infectieuses et Tropicales CHR ORLEANS La SOURCE, Orléans
Hospital Universitari i Politecnic La Fe, Valencia
Klinikum der Universitat Zu Koln, Cologne
University of Bonn, Med J. Immunologische Siudienzenirale, Bonn
Johann Wolfgang Goethe-University Hospital, Medical HIVCENTER, Frankfurt
Fundacion IDEAA, Buenos Aires
Hospital Italiano de Buenos Aires, Buenos Aires
Hospital G de Agudos JM Ramos Mejia, Buenos Aires
CAICI, Rosario
Hospital Privado- Centro Medico Cordoba, Córdoba
Fundación Arriarán, Santiago
INCMNSZ, Mexico City
St. Thomas's Hospital, London
Western General Hospital, Edinburgh
Southern Alberta Clinic, Calgary
University Health Network/Toronto General Hospital, Toronto
Canadian Immunodeficiency Research Collaborative (CIRC) lnc (Maple Leaf Clinic), Toronto
Clinic Opus/Lori, Montreal
Nagoya Medical Center, Nagoya
Wojewodzki Szpital Zakazny Centrum Diagnostyki i Terapii AIDS, Warsaw
Hospital Germans Trias i Pujol, Badalona
Hospital Clínic de Barcelona, Barcelona
Hospital de la Santa Creu i Sant Pau, Barcelona
St. Mary's Hospital, Imperial College, London
Brighton & Sussex University NHS Trust, Brighton
Coventry and Warwickshire Partnership Trust, Coventry
Lead Sponsor
Collaborators (2)
ViiV Healthcare
INDUSTRY
Pfizer
INDUSTRY
Kirby Institute
OTHER_GOV